Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

2.
4.
7.

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.

Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM.

Virology. 2001 Jul 5;285(2):193-203.

8.

Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.

Wang J, Li D, Bambara RA, Dykes C.

J Gen Virol. 2013 Oct;94(Pt 10):2297-308. doi: 10.1099/vir.0.054999-0. Epub 2013 Jun 26.

9.

A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Nikolenko GN, Delviks-Frankenberry KA, Pathak VK.

J Virol. 2010 May;84(10):5238-49. doi: 10.1128/JVI.01545-09. Epub 2010 Mar 10.

10.

In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.

Sato A, Hammond J, Alexander TN, Graham JP, Binford S, Sugita K, Sugimoto H, Fujiwara T, Patick AK.

Antiviral Res. 2006 Jun;70(2):66-74. Epub 2006 Jan 25.

PMID:
16472877
11.
12.

Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.

Tambuyzer L, Azijn H, Rimsky LT, Vingerhoets J, Lecocq P, Kraus G, Picchio G, de B├ęthune MP.

Antivir Ther. 2009;14(1):103-9.

PMID:
19320243
13.

F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.

Lu X, Liu L, Zhang X, Lau TC, Tsui SK, Kang Y, Zheng P, Zheng B, Liu G, Chen Z.

Antimicrob Agents Chemother. 2012 Jan;56(1):341-51. doi: 10.1128/AAC.05537-11. Epub 2011 Oct 28.

14.

Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones.

Arion D, Sluis-Cremer N, Min KL, Abram ME, Fletcher RS, Parniak MA.

J Biol Chem. 2002 Jan 11;277(2):1370-4. Epub 2001 Oct 29.

15.

Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.

Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ.

Antimicrob Agents Chemother. 2010 May;54(5):1973-80. doi: 10.1128/AAC.00870-09. Epub 2010 Mar 1.

16.

Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.

Shaw-Reid CA, Feuston B, Munshi V, Getty K, Krueger J, Hazuda DJ, Parniak MA, Miller MD, Lewis D.

Biochemistry. 2005 Feb 8;44(5):1595-606.

PMID:
15683243
18.

Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone.

Borkow G, Fletcher RS, Barnard J, Arion D, Motakis D, Dmitrienko GI, Parniak MA.

Biochemistry. 1997 Mar 18;36(11):3179-85.

PMID:
9115994
19.

Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function.

Palaniappan C, Wisniewski M, Jacques PS, Le Grice SF, Fay PJ, Bambara RA.

J Biol Chem. 1997 Apr 25;272(17):11157-64.

20.

Drug targeting of HIV-1 RNA.DNA hybrid structures: thermodynamics of recognition and impact on reverse transcriptase-mediated ribonuclease H activity and viral replication.

Li TK, Barbieri CM, Lin HC, Rabson AB, Yang G, Fan Y, Gaffney BL, Jones RA, Pilch DS.

Biochemistry. 2004 Aug 3;43(30):9732-42.

PMID:
15274628

Supplemental Content

Support Center